💥 Dragon Pharma

P21

✔️ Substance: CDKN1A, CAP20, P012
✔️ Price For: Vial 5 mg
✔️ Brand: Dragon Pharma

Out of stock

Dragon Pharma P21

IDENTITYCompound P21 Peptide / CDKN1A Related Compound
SubstanceCDKN1A, CAP20, P012
Strength5 mg
FormLyophilized Vial
ClassResearch Compound

PHARMACOLOGYTargetCell Cycle Regulation Pathways
Protein PathwayCDKN1A / p21 Signaling
FunctionCellular Growth Regulation
CategoryPeptide Research Compound
Clinical StatusResearch Use

SAFETY PROFILEHuman ApprovalNot Established
ToxicologyResearch Evaluation Required
Hormonal EffectNo Direct Androgen Activity
Liver ImpactNot Classified
PCTNot Applicable

STORAGE & PACKAGEBrandDragon Pharma
Package5 mg Multi-dose Vial
Storage2–8°C Recommended
ProtectionProtect From Light
FormFreeze-Dried Powder

USAGE INFORMATIONUsageCellular Research Applications
AdministrationSubcutaneous Research Administration
Dosage Formatmcg/day or mg/week Research Range
Duration4–12 Weeks Research Period
Monitoring Laboratory Evaluation Recommended

BODYBUILDING USAGEPurposeCellular Recovery Research
Muscle GrowthIndirect Research Interest
RecoveryCellular Adaptation Studies
Fat LossNo Direct Thermogenic Action
PerformanceExperimental Application

DOSING PROFILEResearch Low Range0.5–1 mg/week
Research Moderate Range1–2 mg/week
Research Higher Range2–5 mg/week
Administration Frequency1–3 Times Weekly
Research Duration4–12 Weeks

ADMINISTRATION PROFILERouteSubcutaneous Injection
PreparationReconstitution Required
Timing Morning or Consistent Daily Schedule
Cycle LengthResearch Period 4–12 Weeks
Storage After MixingRefrigerated Conditions

RECOVERY & DISCONTINUATIONPCTNot Required
Hormonal RecoveryNo HPTA Suppression Expected
StoppingGradual Research Discontinuation
MonitoringBiomarker Evaluation
Follow UpResearch Assessment

MECHANISM OF ACTIONPrimary Pathwayp21/CDKN1A Signaling
Cell CycleRegulation Mechanisms
DNA ResponseCellular Stress Pathways
Protein TargetCDKN1A Expression
Research AreaCellular Biology

PHARMACOKINETICSReleasePeptide-Based Profile
MetabolismProteolytic Pathways
Half-lifeNot Fully Established
DistributionResearch Dependent
ClearanceBiological Degradation

CHEMICAL PROFILECompound TypePeptide Research Molecule
Primary MarkerCDKN1A / p21
Sequence CAP20 / P012 Research Structure
Molecular DataNot Fully Established
Classification Cell Signaling Research Compound

COMPATIBILITYRecovery ResearchPeptide Based Compounds
Training SupportExperimental Application
Hormonal CompoundsNo Direct Interaction Established
Nutritional SupportProtein & Recovery Focus
MonitoringBiomarker Tracking

OVERVIEW

Dragon Pharma P21 5 mg is a peptide-based research compound associated with the CDKN1A (p21) cellular pathway. CDKN1A is a cyclin-dependent kinase inhibitor involved in regulation of cell cycle progression, DNA response mechanisms, and cellular growth control.

Within bodybuilding research discussions, P21-related compounds are investigated for potential links between cellular regulation, recovery processes, and tissue adaptation.

POTENTIAL RESEARCH BENEFITS

Supports cellular signaling research
Investigates CDKN1A pathway activity
Associated with cell cycle regulation studies
Potential interest in recovery research
Non-androgenic mechanism profile
No direct estrogenic conversion
Peptide-based research application

POTENTIAL RISKS

Limited human clinical data
Long-term effects not established
Research compound classification
Possible injection-related reactions
Unknown individual response
Requires scientific monitoring
Not approved as bodybuilding medication

PERFORMANCE PROFILE

Cellular Research

80%

Recovery Interest

65%

Direct Muscle Gain

20%

Hormonal Activity

10%

Experimental Use

75%

WHAT IS DRAGON PHARMA?

Dragon Pharma is a pharmaceutical brand recognized in bodybuilding communities for manufacturing performance-oriented products, including anabolic compounds, peptides, and research materials. Brand reputation, manufacturing standards, product authentication, and quality control remain important considerations when evaluating any pharmaceutical-related product.

WHY CHOOSE DRAGON PHARMA?

Recognized bodybuilding pharmaceutical brand presence
Focus on pharmaceutical-style product presentation
Wide range of performance research compounds
Consistent vial-based packaging format
Strong brand recognition among athletes
Product-specific identification and labeling

CONCLUSION

Dragon Pharma P21 5 mg represents a peptide-based research compound associated with the CDKN1A/p21 cellular signaling pathway. Its mechanism differs from traditional bodybuilding compounds because it does not act as an anabolic steroid, androgen receptor agonist, or hormone replacement product.

Research interest surrounding P21 focuses on cellular regulation, biological signaling, and potential applications in understanding recovery-related pathways. Current information remains limited, and scientific evaluation is required before drawing conclusions regarding performance enhancement.

The compound should be approached as a research molecule rather than a conventional bodybuilding drug. Responsible handling, accurate identification, and appropriate scientific monitoring are essential.

DISCLAIMER

This information is provided for educational and scientific reference purposes only. Dragon Pharma P21 is described as a research compound and is not presented as an approved treatment, medication, or performance-enhancing recommendation. Always follow applicable regulations and seek professional medical guidance regarding pharmaceutical substances.